Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.
about
d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophreniaA novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypal personality disorder: altered l-serine level associated with disruption of PSAT1 gene expressionCircuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaFunctional alterations of astrocytes in mental disorders: pharmacological significance as a drug targetIn vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophreniaMeta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophreniaNegative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS studyAntipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotectionGlutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion.Neonatal disruption of serine racemase causes schizophrenia-like behavioral abnormalities in adulthood: clinical rescue by d-serineEffects of the antioxidant sulforaphane on hyperlocomotion and prepulse inhibition deficits in mice after phencyclidine administration.The association of schizophrenia risk D-amino acid oxidase polymorphisms with sensorimotor gating, working memory and personality in healthy males.Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?Effect of amphetamine on extracellular concentrations of amino acids in striatum in neurotensin subtype 1 and 2 receptor null mice: a possible interaction between neurotensin receptors and amino acid systems for study of schizophrenia.Genetic loss of D-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice.Glycine transport inhibitors for the treatment of schizophreniaWhen top-down meets bottom-up: auditory training enhances verbal memory in schizophreniaSerine racemase is associated with schizophrenia susceptibility in humans and in a mouse model.Targeted disruption of serine racemase affects glutamatergic neurotransmission and behaviorA role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in miceGlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric DisordersConsensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics.Clinical and biochemical study of d-serine metabolism among schizophrenia patients.A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry studyThe neurobiology of D-amino acid oxidase and its involvement in schizophrenia.Decreased free d-aspartate levels are linked to enhanced d-aspartate oxidase activity in the dorsolateral prefrontal cortex of schizophrenia patientsReduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode PsychosisQuantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients.Pharmacological characterization of [³H]CHIBA-3007 binding to glycine transporter 1 in the rat brainSerum glutamine, set-shifting ability and anorexia nervosa.Free D-aspartate regulates neuronal dendritic morphology, synaptic plasticity, gray matter volume and brain activity in mammalsNovel therapeutic drugs for neuropsychiatric disordersMolecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia.Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.The DAO gene is associated with schizophrenia and interacts with other genes in the Taiwan Han Chinese population.The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia.Reduced cortical thickness is associated with the glutamatergic regulatory gene risk variant DAOA Arg30Lys in schizophrenia.Sex-based differences in gene expression in hippocampus following postnatal lead exposure.
P2860
Q24294371-C67CDA91-ED45-4D02-A76A-EE92A6788921Q24607731-B920F980-4B3E-4DDC-A5F5-29BD5B2B1818Q24646206-A17F7F6A-8E01-4F05-8C22-881A2A0ED2BDQ26798948-248F70C0-3E70-4A37-B698-0213099A3F27Q28083121-46B24C38-5453-4AD3-AFE8-108C15206408Q28248687-62E2A56F-22AF-4E89-9870-F6271BA0B450Q28472479-7E332AA0-D41A-440E-BABA-B5651A1FA2B7Q30386608-B6E0556C-BF38-4A6E-BF3E-7DCDA0A43768Q30387014-88F73DBD-1872-4D6D-AFF3-1A8B17C97D87Q30447828-5F2DD178-AB9E-4955-A79C-90FFD120D5A6Q30455182-F330A9BE-70E7-459A-BF48-88041C4F9B7BQ30458051-A05D22D8-1551-4711-9C0D-EBEF435BB5E9Q30466238-068E98C9-F127-42C9-90AB-81B56991ADBEQ30473410-CED532A1-1A61-46F9-8F0D-EC51CCBDA62BQ30474021-815123EB-F226-448D-90EC-3A21C3CF48F5Q30475349-B41164CC-7D9D-40D7-8B55-846D8C43835FQ30477241-3A4CC483-0DF4-45B7-B3D9-2073A94DEFFEQ30477522-C96A046D-6FE6-42CF-BEC6-869F64E6F956Q30478986-CD911424-FC9F-4B63-8D7D-3FC4E63E3BC3Q30479725-C6D29914-4815-4D72-96E6-AD901A289A49Q30484413-268183C4-9AA9-4D40-9CC5-B8521C5D004BQ30651885-0BE46976-2B64-4DE6-8BE5-DD5EF5585B89Q30756194-55E2B2B7-7388-4289-B183-405926BDD1A6Q31108616-060150AE-594B-432D-B988-3985494F47DBQ33565101-0A652CED-780C-401D-8231-0CF12BF9DA1DQ33575018-8986C404-AC1E-4A4C-8902-25950E613622Q33611796-8C3927B9-C235-4D96-9075-674FF2B8BDC7Q33718794-57538492-428A-40AA-916F-6D190EAC47BAQ33720060-F3A7A181-0C87-4775-BCED-B96A5217D97EQ33863985-5C64BDCA-A00F-483A-BA56-1FE718518E76Q33952310-0BBFD70D-6AD8-4B9C-8150-FF0A44E098F9Q33986685-82651F2B-A7FE-45B3-B9B1-5660FEFCEFBEQ33990671-9A17D9C6-6A9F-4B57-9943-C38264FE8F58Q34018299-C4CC6E8D-F8A2-4B53-89CB-96EA171F1EFAQ34306261-26AE11E6-5EAA-4A37-8CD0-558F0662924AQ34330678-47B4B5A5-6E59-495E-BC12-7FA5EBD5DC10Q34653284-380187EE-19D1-416E-9740-84F74C63AAA3Q34970798-39C3A691-FD52-4328-9745-72F493206F46Q35112156-69F6B64E-D7D8-4720-BAE0-CD27792DD5A4Q35243565-2102ED09-A120-48F6-8CFB-C6E13966BA92
P2860
Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Decreased serum levels of D-se ...... n hypothesis of schizophrenia.
@ast
Decreased serum levels of D-se ...... n hypothesis of schizophrenia.
@en
type
label
Decreased serum levels of D-se ...... n hypothesis of schizophrenia.
@ast
Decreased serum levels of D-se ...... n hypothesis of schizophrenia.
@en
prefLabel
Decreased serum levels of D-se ...... n hypothesis of schizophrenia.
@ast
Decreased serum levels of D-se ...... n hypothesis of schizophrenia.
@en
P2093
P1433
P1476
Decreased serum levels of D-se ...... on hypothesis of schizophrenia
@en
P2093
Chikara Kumakiri
Eiji Shimizu
Hiroyuki Watanabe
Hisanori Hasegawa
Kazuhiro Imai
Masaomi Iyo
Michiko Nakazato
Naoya Komatsu
Naoyuki Shinoda
Shin-ichi Okada
P304
P356
10.1001/ARCHPSYC.60.6.572
P407
P50
P577
2003-06-01T00:00:00Z